周一，部分生物科技股盘前下跌，截至发稿， Capricor Therapeutics Inc跌超9%， Sarepta Therapeutics 跌超7%， Replimune Group Inc. 跌5.67%。有消息称，被解职的美国食品药品监督管理局（FDA）疫苗监管者维奈・普拉萨德将重返该机构。
普拉萨德曾在与基因疗法相关的死亡事件发生后，下令 Sarepta 公司停止其杜氏肌营养不良症治疗药物的发货。7 月 29 日，在遭到保守派的强烈反对后，他突然离开了该机构。尽管普拉萨德将重新执掌生物制品评价与研究中心，但目前尚不清楚他是否还会同时担任此前在该机构担任的另外两个职位 —— 首席科学官和首席医疗官。
今年 5 月，当普拉萨德被任命为生物制品与研究中心负责人时，鉴于他对新冠疫苗的立场，疫苗和免疫疗法相关股票曾出现下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
